What ICC International Cannabis does:
ICC International Cannabis Corp.??s (CSE:WRLD.U)(OTCMKTS:WLDCF) has an ambitious corporate mandate, to plan, design, build and operate the highest quality, lowest cost Cannabis production, processing and distribution facilities worldwide.
The Vancouver-based company boasts an in-depth understanding of both the cannabis and biomedical industries, as well as world-class experience within the many associated cannabis industry vehicles and derivatives.
The group aims to contribute financial, operational and management catalysts to its selected industry partners. These strategic contributions are aimed to afford the company’s partners elevated abilities to expand core business units, while permitting autonomy and a continued focus on innovation.
Supplemented by capital infusion and debt restructuring opportunities, ICC provides its partners with a variety of tailored value add service offerings including brand awareness, product positioning, cultivation and manufacturing expertise, as well as legal, financial and regulatory guidance.
Among its investments and partnerships:
- ICC has secured the exclusive European master license to the Affinity Alpha Unit, a revolutionary cannabinoid extraction system
- Inked a licensing agreement with Authentic Brands Group to market and distribute cannabidiol-derived health and wellness products throughout Europe under brands such as Marilyn Monroe, Elvis Presley, Greg Norman.
- Completed a US$1.2 million strategic investment into Biotii Technologies Corp., a Boston, Mass.-based private biotechnology company actively pursuing genetically engineered micro-organisms that express cannabinoid profiles identical to those found in nature
- Launched Buy Well Care Ecosystems, the first European Guaranteed Issue Medical Cannabis Coverage in collaboration with Evergreen Pacific and Cannops to introduce transformative extended healthcare coverages, including cannabinoid therapeutic coverage, to the European marketplace
Well-established integrated cannabis company Auxly Cannabis Group Inc (OTC:CBWTF) - formerly known as Cannabis Wheaton Income Corp. – has made a $5 million strategic investment into ICC International Cannabis Corp. by way of convertible debentures.
Auxly’s strategic investment expanded its operational capabilities to Denmark, Slovenia, Lesotho, Colombia and South Africa and ICC’s potential distribution network through the relationship with Cosmos Holdings, pending legalization of medical cannabis, to Germany, UK, Ireland, UAE, Denmark, Italy, France, Singapore, Spain, Lebanon, Macedonia, Jordan, Sweden, Poland, Netherlands and Greece.
In July, UK-listed tobacco giant Imperial Brands PLC said it would invest approximately $123 million in Auxly by way of a convertible debenture and grant the company global licences to its vaping technology and access to its vapor innovation business, Nerudia.
How is it doing:
ICC has its fingers in a number of cannabis-related pies globally, and in the past few months has signed deals for cannabinoid vending machines in Europe, medicinal cannabis supply in New Zealand, and pharmacies in Columbia.
At the start of June, the firm announced the acquisition of the international rights to a self-dispensing THC/CBD vending machine.
The company plans to deploy the vending machines into its existing network of 80,000 high-traffic retail endpoints and pharmacies across Europe.
The proprietary technology that runs the vending machines, or kiosks, is currently owned by VendaPharm EU LLC. Under a distribution and software licensing agreement, ICC said it will acquire 100% of VendaPharm’s outstanding shares.
ICC said the vending machines are equipped with facial-recognition software and camera, high-definition LED customer display, temperature-controlled storage, data aggregation and keyless entry, among other features. The kiosks also accept debit and credit cards as well as fiat currencies.
The machines will offer customers a suit of CBD products, including balms, roll-ons, healing sticks and vaporizers. Pet owners will be able to buy CBD gels and tinctures. Also, machines will carry hemp oil-derived cosmetics with anti-aging properties and cannabis-light pre-rolled cigarettes.
Away from vending, in July, the company revealed that it had signed an exclusive supply and commercial rights agreement with medical cannabis company NUBU Pharmaceuticals in New Zealand.
Under the terms of the agreement, ICC will supply NUBU with a suite of full-spectrum pharmaceutical grade medical cannabis products.
Founded in 2017, NUBU Pharmaceuticals is a first mover within New Zealand’s high-value medical cannabis industry. Earlier this year, NUBU received a license to deal in controlled drugs by New Zealand’s Ministry of Health, as well as a license to sell medicines wholesale, which will allow the company to import and distribute ICC manufactured THC/CBD products ahead of other local market participants.
The previous month, ICC had taken a step closer to making its cannabis cultivation facility fully operational with the completion of a technical feasibility study for a 150,000-square foot facility located in Møldrup, Denmark.
READ: ICC International Cannabis says Danish facility could produce 20 million grams of dried cannabis flower per year
The study revealed that, once fully operational, the facility will have the capacity to produce around 20 million grams of premium dried cannabis flower to sell to medicinal markets.
ICC said it is also planning on pursuing outdoor cultivation opportunities on the land package’s 45 acres, where preliminary soil sampling indicated ideal conditions for outdoor grow.
Once the outdoor agricultural program is implemented, ICC said it is forecasted to yield 81,000 kilograms of dried cannabis in the 2020 harvest season from its crops.
ICC is running capacity simulations scenarios to help refine cost estimations while maintaining optimal production, and is looking for non-dilutive, project level debt financing for the new facility.
Also in June, the company acquired a second brick-and-mortar pharmacy operation in Colombia, paying C$230,000 to buy Grupo Pharma Colombiano Inc’s pharmacy as well as issuing 15 million common shares to Grupo Pharma’s shareholders.
Grupo Pharma controls 75% of the pharmacy operation that sells both THC and CBD products. It is located in the ‘El Poblado’ area of Medellin, and the deal will help the Canadian company strengthen its footprint in Colombia’s burgeoning medical cannabis industry.
In May, ICC inked a pact to acquire AgraFlora Organics International Inc’s Colombian pharmacy operation, Farma Swiss SAS, for $250,000 in stock.
ICC said then that it plans to acquire “eight additional locations” in Colombia by the end of fiscal 2019.
The company also inked a cannabinoid pharmaceutical advisory agreement in July with cannabinoid expert Dr. Alexandros Makriyannis, an advisor to Pfizer, Bristol-Myers Squibb, and Biogen.
Under the agreement, Dr. Makriyannis - a professor of Chemistry and Chemical Biology at Northeastern University, renowned for various cannabinoid-based accomplishments, such as the discovery of cannabinoid receptor antagonists - will help in ICC’s search to biosynthesize cannabinoids identical to those found in nature.
What the boss says:
In June, ICC’s CEO David Shpilt said: “According to a report by New Frontier Data, the total addressable Latin American cannabis market represents approximately US$9.8 billion and accounts for 600 million people, further validating Colombian’s high-profile market opportunity.”